| Literature DB >> 36039028 |
Long Huang1, Qingsheng Yu1, Hui Peng1, Zhou Zhen2.
Abstract
BACKGROUND Portal hypertension associated with liver cirrhosis can be treated by splenectomy. During splenectomy, the gastrosplenic and the splenorenal ligaments that form the hilar splenic pedicle can be surgically divided by several approaches, with the aim to reduce portal vein thrombosis (PVT) and postoperative pancreatic fistula (PPF). This 12-year retrospective study from a single center aimed to evaluate postoperative outcomes following use of a modified method of surgical division of the splenic pedicle (MSDSP) in 719 patients who underwent splenectomy for portal hypertension (PH). MATERIAL AND METHODS From January 2010 to December 2021, 719 consecutive cirrhotic patients with PH and splenomegaly underwent splenectomy in our department. According to different methods of surgical division of the splenic pedicle, patients were divided into a Control Group (n=349) and a Study Group (n=370). The characteristics of the patients, perioperative indicators, postoperative complications (PVT, PPF and abdominal hemorrhage) and follow-up data were compared between the 2 groups. Propensity score matching was conducted to adjust for differences in preoperative characteristics at a 1: 1 ratio, resulting in 260 patients in each group. RESULTS After PSM was conducted, intraoperative blood loss, PVT, PPF, and hospital stay were decreased significantly in the matched Study Group (all P<0.01). Both groups showed similar results concerning recurrent esophagogastric variceal bleeding and overall survival during the follow-up period. CONCLUSIONS Our MSDSP help to reduce postoperative complications and shorten hospital stay.Entities:
Mesh:
Year: 2022 PMID: 36039028 PMCID: PMC9440622 DOI: 10.12659/MSM.937763
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1Classification and flow diagram of the study population. ITP – idiopathic thrombocytopenic purpura; HS – hereditary spherocytosis; PSM – propensity score matching.
Figure 2Comparison of the 2 splenic pedicle division methods. (A) Conventional splenic pedicle division method; (B) Emergency treatment of splenic pedicle hemorrhage by conventional splenic pedicle division method; (C) Modified splenic pedicle division method; (D) Tertiary splenic pedicle vessels division.
Figure 3The development of technical optimization and innovation for splenectomy. MSDSP – modified method of surgical division of the splenic pedicle; CSDSP – conventional method of surgical division of the splenic pedicle; PVT – portal vein thrombosis; PPF – postoperative pancreatic fistula; TPO – thrombopoietin.
Comparison of the backgrounds of included patients between the 2 groups by PSM analysis.
| Variables | Unmatched |
| Matched |
| ||
|---|---|---|---|---|---|---|
| Control group (n=349) | Study group (n=370) | Control group (n=260) | Study group (n=260) | |||
| Age (years) | 32.7±15.0 | 33.5±14.7 | 0.47 | 32.8±15.0 | 33.2±14.8 | 0.77 |
| Sex, n (%) | 0.72 | 0.93 | ||||
| Male | 199 (57.0) | 206 (55.7) | 148 (56.9) | 147 (56.5) | ||
| Female | 150 (43.0) | 164 (44.3) | 112 (43.1) | 113 (43.5) | ||
| Etiology o cirrhosis, n (%) | 0.89 | 0.93 | ||||
| HLD cirrhosis | 267 (76.5) | 295 (79.7) | 205 (78.9) | 204 (78.5) | ||
| HBV cirrhosis | 62 (17.8) | 64 (17.3) | 41 (15.8) | 46 (17.7) | ||
| HCV cirrhosis | 9 (2.6) | 3 (0.8) | 8 (3.1) | 3 (1.2) | ||
| Schistosomiasis cirrhosis | 1 (0.3) | 2 (0.5) | 1 (0.4) | 2 (0.8) | ||
| Alcoholic cirrhosis | 1 (0.3) | 2 (0.5) | 1 (0.4) | 2 (0.8) | ||
| Autoimmunity cirrhosis | 7 (2.0) | 3 (0.8) | 2 (0.8) | 2 (0.8) | ||
| Unknown | 2 (0.6) | 1 (0.3) | 2 (0.8) | 1 (0.4) | ||
| Child-Pugh classification, n (%) | 0.19 | 0.65 | ||||
| A | 262 (75.1) | 259 (70.0) | 194 (74.6) | 187 (71.9) | ||
| B | 82 (23.5) | 107 (28.9) | 61 (23.5) | 70 (26.9) | ||
| C | 5 (1.4) | 4 (1.1) | 5 (1.9) | 3 (1.2) | ||
| The size of spleen (mm) | ||||||
| Longitudinal diameter of spleen | 180.3±33.0 | 176.5±30.6 | 0.11 | 175.8±31.5 | 178.0±31.6 | 0.41 |
| Thickness of spleen | 69.0±16.8 | 72.3±16.4 | 0.01 | 70.9±16.8 | 70.9±16.1 | 0.99 |
| The diameter of portal vein system (cm) | ||||||
| Portal vein | 1.5±0.2 | 1.4±0.2 | P<0.01 | 1.4±0.2 | 1.4±0.2 | 0.38 |
| Splenic vein6 | 1.3±0.5 | 1.2±0.3 | P<0.01 | 1.3±0.2 | 1.3±0.3 | 0.43 |
| Preoperative blood examination | ||||||
| WBC (109/L) | 2.8±1.7 | 3.0±2.0 | 0.11 | 2.8±1.6 | 2.8±1.4 | 0.78 |
| RBC (1012/L) | 3.9±0.7 | 4.8±16.8 | 0.32 | 3.9±0.7 | 3.9±0.6 | 0.98 |
| HGB (g/L) | 108.8±18.1 | 110.0±18.9 | 0.38 | 109.2±18.5 | 110.4±19.4 | 0.51 |
| PLT (109/L) | 51.7±31.4 | 49.7±36.0 | 0.42 | 50.7±30.3 | 49.4±36.7 | 0.64 |
| TBIL (μmol/L) | 23.2±16.1 | 23.4±15.6 | 0.89 | 23.7±16.5 | 23.6±15.6 | 0.95 |
| ALT (U/L) | 31.2±16.8 | 33.0±32.5 | 0.37 | 31.3±18.0 | 31.3±16.2 | 0.99 |
| AST (U/L) | 33.6±17.3 | 33.6±22.5 | 0.99 | 32.5±15.5 | 32.3±13.1 | 0.90 |
| ALB (g/L) | 37.9±6.3 | 37.7±5.0 | 0.62 | 38.4±6.5 | 37.8±4.8 | 0.28 |
| PT (s) | 15.0±2.4 | 15.5±7.8 | 0.31 | 15.1±2.6 | 15.0±2.2 | 0.61 |
| PT-INR | 1.5±2.8 | 1.5±1.5 | 0.73 | 1.6±3.2 | 1.5±1.8 | 0.67 |
| D-dimer (mg/L) | 0.5±1.2 | 0.6±0.8 | 0.23 | 0.5±1.3 | 0.6±0.8 | 0.74 |
| Variceal hemorrhage history, n (%) | 0.06 | 1 | ||||
| Yes | 57 (16.3) | 81 (21.9) | 47 (18.1) | 47 (18.1) | ||
| No | 292 (83.7) | 289 (78.1) | 213 (81.9) | 213 (81.9) | ||
| Operation, n (%) | ||||||
| Splenectomy only | 307 (88.0) | 324 (87.6) | 0.87 | 227 (87.3) | 229 (88.1) | 0.79 |
| Concomitant pericardial devascularization | 42 (12.0) | 46 (12.4) | 33 (12.7) | 31 (11.9) | ||
| Operation period, n (%) | P<0.01 | 0.96 | ||||
| Early-period | 185 (53.0) | 103 (27.8) | 104 (40.0) | 98 (37.7) | ||
| Intermediate-period | 101 (28.9) | 140 (37.8) | 93 (35.8) | 106 (40.8) | ||
| Late-period | 63 (18.1) | 127 (34.3) | 63 (24.2) | 56 (21.5) | ||
PSM – propensity score matching; HLD – hepatolenticular degeneration; HBV – hepatitis B virus; HCV – hepatitis C virus; WBC – white blood cell; RBC – red blood cell; HGB – hemoglobin; PLT – platelet; ALT – alanine aminotransferase; AST – aspartate aminotransferase; ALB – albumin; TBIL – total bilirubin; PT – prothrombin time.
Comparison of the outcomes of included patients between the 2 groups by PSM analysis.
| Variables | Unmatched |
| Matched |
| ||
|---|---|---|---|---|---|---|
| Control group (n=349) | Study group (n=370) | Control group (n=260) | Study group (n=260) | |||
| Intraoperative outcomes | ||||||
| Intraoperative blood loss (mL) | 309.5±198.8 | 204.6±104.5 | P<0.01 | 316.0±212.2 | 200.8±103.7 | P<0.01 |
| Operation time (min) | 172.4±35.4 | 196.2±34.6 | P<0.01 | 173.1±36.3 | 199.4±34.7 | P<0.01 |
| Postoperative complications, n (%) | ||||||
| PVT | 148 (42.4) | 81 (21.9) | P<0.01 | 124 (47.7) | 55 (21.2) | P<0.01 |
| PPF | 40 (11.5) | 13 (3.5) | P<0.01 | 34 (13.1) | 10 (3.9) | P<0.01 |
| Postoperative abdominal hemorrhage | 10 (2.9) | 5 (1.4) | 0.16 | 8 (3.1) | 5 (1.9) | 0.40 |
| Hospital stay (day) | 13.8±3.1 | 13.0±2.2 | P<0.01 | 14.0±3.4 | 12.8±1.9 | P<0.01 |
PSM – propensity score matching; PVT – portal vein thrombosis; PPF – postoperative pancreatic fistula.
Figure 4The follow-up data comparing the 2 groups. (A) Cumulative hazard of recurrent EGVB; (B) Overall survival. EGVB – esophagogastric variceal bleeding.
Follow-up data of the 2 groups.
| Variables | Control group (n=312) | Study group (n=321) | |
|---|---|---|---|
| Follow-up duration (months), median (Q1, Q3) | 77.5 (46, 112) | 67 (36, 104) | 0.01 |
| Treatment method, n (%) | |||
| Drug and infusion treatment | 7 (2.2) | 8 (2.5) | 0.84 |
| Endoscopy treatment | 5 (1.6) | 4 (1.2) | 0.71 |
| Death, n (%) | 4 (1.3) | 3 (0.9) | 0.40 |
| REGVB rate, n (%) | 0.66 | ||
| 1-year | 5 (1.6) | 4 (1.3) | |
| 3-year | 7 (2.2) | 7 (2.2) | |
| 5-year | 9 (2.9) | 10 (3.1) | |
| >5-year | 12 (3.9) | 12 (3.7) | |
| OS rate, n (%) | 0.63 | ||
| 1-year | 311 (99.7) | 321 (100) | |
| 3-year | 309 (99.0) | 320 (99.7) | |
| 5-year | 308 (98.7) | 319 (99.4) | |
| >5-year | 308 (98.7) | 318 (99.1) |
REGVB – recurrent esophagogastric variceal bleeding; OS – overall survival.